Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
Novocure Limited (NASDAQ: NVCR) is a global oncology company centered on Tumor Treating Fields (TTFields) therapy, and its news flow reflects both commercial performance and clinical development across aggressive solid tumors. Company press releases emphasize TTFields-based products such as Optune Gio for glioblastoma and Optune Lua for metastatic non-small cell lung cancer (mNSCLC) and mesothelioma-related indications.
Investors following NVCR news will find regular updates on quarterly and annual net revenues, active patient counts on TTFields therapy, and geographic contributions from the United States and international markets. Novocure frequently reports metrics for Optune Gio and Optune Lua prescriptions, active patients by indication and region, and recognized revenue from specific products and partnerships.
News coverage also highlights clinical and regulatory milestones. Novocure issues announcements on Phase 2 and Phase 3 trials such as PANOVA-3 and PANOVA-4 in pancreatic cancer, TRIDENT in newly diagnosed glioblastoma and METIS in brain metastases from NSCLC. Releases describe key outcomes, including when pivotal trials meet primary endpoints or support regulatory submissions. The company also reports on premarket approval (PMA) applications to the U.S. Food and Drug Administration for new TTFields indications and approvals from regulators such as Japan’s Ministry of Health, Labour and Welfare for Optune Lua.
Another recurring theme in NVCR news is participation in major healthcare and oncology conferences, including the J.P. Morgan Healthcare Conference, Jefferies Global Healthcare Conference, Piper Sandler Healthcare Conference, EANO, ESMO and ASTRO. These events often feature Novocure management presentations, investor meetings and scientific data on TTFields therapy.
For readers tracking NVCR, this news page aggregates company announcements on financial results, product approvals, clinical trial data, leadership changes and scientific presentations, offering a consolidated view of developments around Novocure’s TTFields-based oncology platform.
Novocure (NASDAQ: NVCR) has scheduled its second quarter 2025 financial results announcement for July 24, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss its financial performance for the three and six-month periods ending June 30, 2025.
The presentation materials will be accessible through Novocure's investor relations website and will remain available for at least 14 days after the call. The company uses its investor relations website to disclose material non-public information in compliance with Regulation FD.
Novocure (NVCR) has announced two upcoming investor events. The company will host a PANOVA-3 Investor Event on May 31, 2025, at 8:00 p.m. ET in Chicago to discuss data from their successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Dr. Vincent Picozzi, a medical oncologist and trial investigator, will join the leadership team to review results.
Additionally, CEO Ashley Cordova will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 p.m. ET. CFO Christoph Brackmann will join for one-on-one investor meetings. Both events will be webcast and available for replay on Novocure's website.
Novocure (NVCR) reported Q1 2025 financial results with net revenues of $155.0 million, up 12% year-over-year. The company achieved 4,268 active patients on Tumor Treating Fields therapy globally as of March 31, 2025.
Key financial metrics include: 75% gross margin, net loss of $34.3 million ($0.31 per share), and cash position of $929.1 million. Regional revenue contributions: US ($93.2M), Germany ($18.7M), France ($17.9M), and Japan ($8.7M).
Notable developments include CE Mark approval for Optune Lua for metastatic NSCLC treatment and upcoming presentation of Phase 3 PANOVA-3 pancreatic cancer trial results at ASCO 2025. The company faces potential tariff impacts of up to $8-11 million in 2025 depending on policy implementation.
Novocure (NASDAQ: NVCR) has received CE Mark approval for Optune Lua® to treat metastatic non-small cell lung cancer (NSCLC) in combination with immune checkpoint inhibitors or docetaxel after platinum-based treatment progression.
The approval is based on the Phase 3 LUNAR trial results, which showed a significant 3.3-month median overall survival extension (13.2 vs 9.9 months, P=0.035). Notably, patients receiving Optune Lua with immune checkpoint inhibitors showed a 7.7-month survival benefit (18.5 vs 10.8 months, P=0.03).
Optune Lua, a wearable device delivering Tumor Treating Fields (TTFields), demonstrated manageable safety with mainly low-grade skin-related events (65.4% of patients). Only 5% experienced Grade 3 events, with no Grade 4 or 5 toxicities reported.
Novocure (NASDAQ: NVCR) has announced it will release its first quarter 2025 financial results on April 24, 2025, before U.S. markets open. The company's management will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss the financial performance for the quarter ending March 31, 2025.
The presentation slides and webcast will be accessible through Novocure's investor relations website and will remain available for a minimum of 14 days after the call.
Novocure (NASDAQ: NVCR) has announced its participation in the upcoming Leerink Global Healthcare Conference scheduled for March 11, 2025. The company's Chief Financial Officer, Christoph Brackmann, will engage in a fireside chat at 4:20 p.m. EST and conduct one-on-one meetings with investors throughout the conference.
Interested parties can access a live audio webcast of the presentation through Novocure's Investor Relations webpage. The recording will remain available for replay for a minimum of 14 days after the event.
Novocure (NVCR) reported strong financial results for Q4 and full year 2024, with total net revenues reaching $605.2 million for the year, up 19% year-over-year. Q4 revenues were $161.3 million, showing a 21% increase.
Key developments include FDA approval of Optune Lua for metastatic non-small cell lung cancer treatment and positive Phase 3 PANOVA-3 trial results for pancreatic cancer. The company maintained 4,126 active patients globally, with 4,077 using Optune Gio for glioblastoma treatment.
Regional Q4 revenues: US ($107.2M), Germany ($17.4M), France ($15.7M), and Japan ($8.5M). Gross margin was 79%. The company reported a quarterly net loss of $65.9 million ($0.61 per share) with adjusted EBITDA of $2.6 million.
Novocure (NVCR) has officially opened its new global headquarters in Baar, Canton of Zug, Switzerland, marking a significant milestone as the company enters its 25th year of business. The oncology company, which develops Tumor Treating Fields (TTFields) therapy for aggressive forms of cancer, has grown its Swiss-based workforce to over 200 people since establishing its first office in Switzerland in 2013.
The new cutting-edge facility features collaborative workspaces and incorporates sustainable technologies, including rooftop solar panels and a reversible air-to-water heat pump for heating and cooling. The company relocated from Root, Canton of Lucerne, choosing Zug for its dynamic life sciences cluster and favorable business environment.
Novocure's commercialized products are approved in certain countries for treating adult patients with glioblastoma, non-small cell lung cancer, and malignant pleural mesothelioma, with ongoing clinical trials exploring TTFields therapy in various cancer types.